197 related articles for article (PubMed ID: 15479778)
1. Calcimimetics and the treatment of primary and secondary hyperparathyroidism.
Joy MS; Kshirsagar AV; Franceschini N
Ann Pharmacother; 2004 Nov; 38(11):1871-80. PubMed ID: 15479778
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
5. Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Goodman WG
Semin Nephrol; 2004 Sep; 24(5):460-3. PubMed ID: 15490411
[TBL] [Abstract][Full Text] [Related]
6. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Goodman WG
Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
[TBL] [Abstract][Full Text] [Related]
7. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
Strippoli GF; Palmer S; Tong A; Elder G; Messa P; Craig JC
Am J Kidney Dis; 2006 May; 47(5):715-26. PubMed ID: 16632010
[TBL] [Abstract][Full Text] [Related]
9. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
10. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
Rybczyńska A; Hoppe A
Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
Franceschini N; Joy MS; Kshirsagar A
Expert Opin Investig Drugs; 2003 Aug; 12(8):1413-21. PubMed ID: 12882626
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
Drugs R D; 2003; 4(6):349-51. PubMed ID: 14584963
[TBL] [Abstract][Full Text] [Related]
13. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
14. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
15. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
17. [Management of secondary hyperparathyroidism].
Cunningham J
Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
[No Abstract] [Full Text] [Related]
18. Cinacalcet hydrochloride.
Barman Balfour JA; Scott LJ
Drugs; 2005; 65(2):271-81. PubMed ID: 15631545
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
20. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]